Revisiting policy on HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis - Hallo friendsTHE LEK NEWS, In the article you read this time with the title Revisiting policy on HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : Revisiting policy on HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis
link : Revisiting policy on HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis

Revisiting policy on HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis

Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis

Waranya Rattanavipapong ,Thunyarat Anothaisintawee ,Yot Teerawattananon

Published: February 21, 2018
https://doi.org/10.1371/journal.pone.0193112

Full Text Article:

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193112

Abstract

Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care’s benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impact of introducing sofosbuvir-based regimens in the tax-based health insurance scheme. The Markov model was constructed to assess costs and benefits of the four treatment options that include: (i) current practice–peginterferon alfa (PEG) and ribavirin (RBV) for 24 weeks in genotype 3 and 48 weeks for other genotypes; (ii) Sofosbuvir plus peginterferon alfa and ribavirin (SOF+PEG-RBV) for 12 weeks; (iii) Sofosbuvir and daclatasvir (SOF+DCV) for 12 weeks; (iv) Sofosbuvir and ledipasvir (SOF+LDV) for 12 weeks for non-3 genotypes and SOF+PEG-RBV for 12 weeks for genotype 3 infection. Given that policy options (ii) and (iii) are for pan-genotypic infection, the cost of genotype testing was applied only for policy options (i) and (iv). Results reveal that all sofosbuvir-based regimens had greater quality adjusted life years (QALY) gains compared with the current treatment, therefore associated with lower lifetime costs and more favourable health outcomes. Additionally, among the three regimens of sofosbuvir, SOF+PEG-RBV for genotype 3 and SOF+LDV for non-3 genotype are the most cost-effective treatment option with the threshold of 160,000 THB per QALY gained. The results of this study had been used in policy discussion which resulted in the recent inclusion of SOF+PEG-RBV for genotype 3 and SOF+LDV for non-3 genotype in the Thailand’s benefit package.

Continue reading online: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193112

Download PDF

Thus Article Revisiting policy on HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis

That's an article Revisiting policy on HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Revisiting policy on HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis with the link address https://theleknews.blogspot.com/2018/02/revisiting-policy-on-hcv-treatment.html

Tweet

Subscribe to receive free email updates: